• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    STRATA Skin Sciences Reinforces Market Leadership Following Key Litigation Milestones Against LaserOptek

    10/20/25 8:00:00 AM ET
    $SSKN
    Medical/Dental Instruments
    Health Care
    Get the next $SSKN alert in real time by email

    HORSHAM, Penn., Oct. 20, 2025 (GLOBE NEWSWIRE) -- STRATA Skin Sciences, Inc. ("STRATA" or the "Company") (NASDAQ:SSKN), a medical technology company dedicated to developing, commercializing, and marketing innovative products for the treatment of dermatologic conditions, today provided an update on its competitive positioning and ongoing litigation against LaserOptek America Corp., LaserOptek Co. Ltd. ("LaserOptek Korea"), and affiliated entities including The Pinnacle Health Group and C. Dalton International.



    Court Recognizes STRATA's Position and Expands Accountability

    As previously disclosed, on November 8, 2024, the U.S. District Court for the Eastern District of Pennsylvania issued an order partially granting STRATA's motion for preliminary injunction. The Court ruled in STRATA's favor, ordering that:

    • LaserOptek and The Pinnacle Health Group — along with their employees, agents, distributors, and affiliates — are enjoined from any sales or marketing of Pallas laser systems in the United States that imply treatments are reimbursable under CPT Codes 96920–96922
    • The defendants are also barred from making false or misleading statements regarding STRATA's excimer laser systems or their own competing products

    In a subsequent decision, the Court also agreed with STRATA's position that LaserOptek Korea should be added as a defendant, citing efforts by the defendants to obscure their involvement. This ruling strengthens STRATA's ability to hold all responsible parties accountable for false advertising and unfair trade practices under the Lanham Act.



    "The Court's decision affirms our commitment to protect both our clinical partners and patients from misleading claims," said Dr. Dolev Rafaeli, STRATA's President and CEO. "By exposing the deceptive tactics used to promote non-excimer lasers under CPT codes reserved for excimer technology, and offering a technology that has no known independent, peer-reviewed clinical validation for the treatment of Psoriasis, or (for that matter) any other inflammatory and autoimmune skin condition whether in or outside the U.S., we are defending not only our business but the ethical and medical standards of the dermatology community. We are happy to report that many dermatology accounts that were deceived with these false advertising claims are now XTRAC excimer laser users leading to our ability to retain and enhance our market share."

    STRATA Regains Market Share and Strengthens Partner Network

    Over the past few months, STRATA has successfully engaged multiple dermatology clinics that were previously misled by false claims about the Pallas solid-state laser's capabilities and reimbursement eligibility.



    To date, over 20 such LaserOptek Pallas buyers have partnered with STRATA on XTRAC excimer laser technology under XTRAC partnership program or purchased XTRAC excimer lasers. These accounts represent over $1 million in annualized capital and recurring revenue, underscoring the resilience and trust in the XTRAC® Excimer Laser, recognized as the gold standard in targeted UVB therapy.

    Expanding Leadership Ahead of New Indications

    There are currently around 1,200 U.S. dermatology clinics that use excimer laser therapy for the treatment and subsequent ethical insurance billing of dermatologic autoimmune conditions such as psoriasis and vitiligo subject to CPT codes 96920 - 96922. All of these clinics are using either the XTRAC or Pharos devices – both are STRATA products. As of June 30, 2025, 844 of these clinics are using excimer laser technology under STRATA's partnership program.

    The STRATA partnership program is suitable for individual dermatology clinic owners, as well as over 358 clinics that are owned by 43 unique private equity backed national accounts, presenting a potential expansion of over 2,000 additional clinics.

    With the recent (May, 2025) American Medical Association CPT Board reaffirming the exclusive use of excimer lasers under codes 96920–96922 through January 1, 2027, STRATA is positioned to expand its leadership as these codes are broadened to include up to 30 dermatologic conditions expanding the available patient population four-fold to all 1,200 users of Excimer laser, allowing them to treat and ethically bill insurance under these codes.



    "The CPT expansion marks a major growth inflection point for STRATA and our 844 partner clinics, as well as all other users of the excimer lasers," added Dr. Rafaeli. "We intend to aggressively defend our market share and ensure that the upcoming inclusion of 30 new indications translates into expanded access for patients and sustainable revenue for our partners, as we will be working with CMS and private payers alike to update their coverage policies."



    Commitment to Integrity and Market Protection

    STRATA continues to take proactive measures to protect the integrity of its intellectual property, technology, and reimbursement framework. The Company remains vigilant against false efficacy or reimbursement claims that risk patient safety and provider compliance.



    "The defendants' actions caused both monetary and reputational damage to STRATA," continued Dr. Rafaeli. "We will pursue every avenue to hold them accountable while continuing to strengthen our network and safeguard the ethical use of clinically backed excimer laser technology and based on our vast clinical foundation and valuable suite of service we offer our partners, are confident in our ability to bring back any provider that was misled."

    About STRATA Skin Sciences, Inc.

    STRATA Skin Sciences is a medical technology company dedicated to developing, commercializing, and marketing innovative products for the in-office treatment of various dermatologic conditions, such as psoriasis, vitiligo, and acne. Its products include the XTRAC® excimer laser, VTRAC® lamp systems, and the TheraClear®X Acne Therapy System.

    STRATA is proud to offer these exciting technologies in the U.S. through its unique Partnership Program. STRATA's popular partnership approach includes a fee per treatment cost structure versus an equipment purchase, installation and use of the device, on-site training for practice personnel, service and maintenance of the equipment, dedicated account and customer service associates, and co-op advertising support to help raise awareness and promote the program within the practice.

    Safe Harbor

    This press release includes "forward-looking statements" within the meaning of the Securities Litigation Reform Act of 1995. These statements include but are not limited to the Company's plans, objectives, expectations and intentions and may contain words such as "will," "may," "seeks," and "expects," that suggest future events or trends. These statements, the Company's ability to launch and sell products recently acquired or to be developed in the future, the Company's ability to develop social media marketing campaigns, direct to consumer marketing campaigns, and the Company's ability to build a leading franchise in dermatology and aesthetics, are based on the Company's current expectations and are inherently subject to significant uncertainties and changes in circumstances. Actual results may differ materially from the Company's expectations due to financial, economic, business, competitive, market, regulatory, adverse market conditions labor supply shortages, or supply chain interruptions resulting from fiscal, political factors, tariffs, international conflicts, responses, or conditions affecting the Company, the medical device industry and our customers and patients in general, as well as more specific risks and uncertainties set forth in the Company's SEC reports on Forms 10-Q and 10-K. Given such uncertainties, any or all these forward-looking statements may prove to be incorrect or unreliable. The statements in this press release are made as of the date of this press release, even if subsequently made available by the Company on its website or otherwise. The Company does not undertake any obligation to update or revise these statements to reflect events or circumstances occurring after the date of this press release. The Company urges investors to carefully review its SEC disclosures available at www.sec.gov and www.strataskinsciences.com.

    Investor Contact:

    CORE IR

    516-222-2560

    [email protected]



    Primary Logo

    Get the next $SSKN alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $SSKN

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $SSKN
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    STRATA Skin Sciences Reinforces Market Leadership Following Key Litigation Milestones Against LaserOptek

    HORSHAM, Penn., Oct. 20, 2025 (GLOBE NEWSWIRE) -- STRATA Skin Sciences, Inc. ("STRATA" or the "Company") (NASDAQ:SSKN), a medical technology company dedicated to developing, commercializing, and marketing innovative products for the treatment of dermatologic conditions, today provided an update on its competitive positioning and ongoing litigation against LaserOptek America Corp., LaserOptek Co. Ltd. ("LaserOptek Korea"), and affiliated entities including The Pinnacle Health Group and C. Dalton International.Court Recognizes STRATA's Position and Expands Accountability As previously disclosed, on November 8, 2024, the U.S. District Court for the Eastern District of Pennsylvania issued an

    10/20/25 8:00:00 AM ET
    $SSKN
    Medical/Dental Instruments
    Health Care

    Excimer Laser Demonstrates Promising Results in Treating Rare Variant of Cutaneous Lymphoma, Mycosis Fungoides

    First English-language case study shows resolution of lesions with 308-nm Excimer laser in rare mycosis fungoides (MF) subtype, poikilodermatous mycosis fungiodes (pMF), underscoring the Company's XTRAC capability to address the condition HORSHAM, Pa., Oct. 14, 2025 (GLOBE NEWSWIRE) -- STRATA Skin Sciences, Inc. ("STRATA" or the "Company") (NASDAQ:SSKN), a medical technology company dedicated to developing, commercializing, and marketing innovative products for the treatment of dermatologic conditions, announces a groundbreaking clinical case study published in Case Reports in Oncology. The study reports the successful use of 308-nm excimer laser to treat a rare and under-recognized form

    10/14/25 8:15:00 AM ET
    $SSKN
    Medical/Dental Instruments
    Health Care

    Marking Eczema Awareness Month – Clinical Research Validates Strata Skin Sciences' XTRAC® Excimer Laser as a Breakthrough Therapy for Localized Atopic Dermatitis

    HORSHAM, Pa., Oct. 03, 2025 (GLOBE NEWSWIRE) -- In recognition of Eczema Awareness Month, STRATA Skin Sciences, Inc. ("STRATA" or the "Company") (NASDAQ:SSKN), a medical technology company dedicated to developing, commercializing, and marketing innovative products for the treatment of dermatologic conditions, highlights the substantial body of peer-reviewed clinical evidence supporting the XTRAC® Excimer Laser (308 nm) as a safe, highly effective treatment for localized atopic dermatitis, the most common form of eczema. This recognition comes as the American Medical Association (AMA) has expanded excimer laser's indications to inflammatory and autoimmune skin diseases, clearing the way for

    10/3/25 10:50:12 AM ET
    $SSKN
    Medical/Dental Instruments
    Health Care

    $SSKN
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Geiger Uri bought $723,999 worth of shares (230,573 units at $3.14) (SEC Form 4)

    4 - STRATA Skin Sciences, Inc. (0001051514) (Issuer)

    7/17/24 5:08:57 PM ET
    $SSKN
    Medical/Dental Instruments
    Health Care

    Large owner Accelmed Partners, L.P. bought $723,999 worth of shares (230,573 units at $3.14), increasing direct ownership by 19% to 1,441,835 units (SEC Form 4)

    4 - STRATA Skin Sciences, Inc. (0001051514) (Issuer)

    7/17/24 5:08:11 PM ET
    $SSKN
    Medical/Dental Instruments
    Health Care

    Chief Executive Officer Rafaeli Dolev bought $59,974 worth of shares (19,100 units at $3.14), increasing direct ownership by 15% to 143,156 units (SEC Form 4)

    4 - STRATA Skin Sciences, Inc. (0001051514) (Issuer)

    7/17/24 5:01:09 PM ET
    $SSKN
    Medical/Dental Instruments
    Health Care

    $SSKN
    SEC Filings

    View All

    $SSKN
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Strata Skin Sciences Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits

    8-K - STRATA Skin Sciences, Inc. (0001051514) (Filer)

    10/16/25 4:30:46 PM ET
    $SSKN
    Medical/Dental Instruments
    Health Care

    SEC Form 424B5 filed by Strata Skin Sciences Inc.

    424B5 - STRATA Skin Sciences, Inc. (0001051514) (Filer)

    10/15/25 4:26:20 PM ET
    $SSKN
    Medical/Dental Instruments
    Health Care

    Strata Skin Sciences Inc. filed SEC Form 8-K: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing

    8-K - STRATA Skin Sciences, Inc. (0001051514) (Filer)

    10/14/25 4:17:37 PM ET
    $SSKN
    Medical/Dental Instruments
    Health Care

    SEC Form 4 filed by Chief Operating Officer Gov Shmuel

    4 - STRATA Skin Sciences, Inc. (0001051514) (Issuer)

    5/15/25 5:21:12 PM ET
    $SSKN
    Medical/Dental Instruments
    Health Care

    SEC Form 4 filed by Chief Accounting Officer Gillings John T

    4 - STRATA Skin Sciences, Inc. (0001051514) (Issuer)

    5/15/25 5:14:28 PM ET
    $SSKN
    Medical/Dental Instruments
    Health Care

    SEC Form 4 filed by Chief Executive Officer Rafaeli Dolev

    4 - STRATA Skin Sciences, Inc. (0001051514) (Issuer)

    5/15/25 5:09:40 PM ET
    $SSKN
    Medical/Dental Instruments
    Health Care

    $SSKN
    Leadership Updates

    Live Leadership Updates

    View All

    Apyx Medical Corporation Appoints Matthew Hill as Chief Financial Officer

    Apyx Medical Corporation (NASDAQ:APYX) ("Apyx Medical;" the "Company"), the manufacturer of a proprietary helium plasma and radiofrequency technology marketed and sold as Renuvion®, today announced the appointment of Matthew Hill to the position of Chief Financial Officer, effective December 4, 2023. Mr. Hill succeeds Tara Semb, whose departure was announced by the Company on November 9, 2023. "Matt joins our executive leadership team with over 30 years of financial and operational experience, more than 20 years of which has been in the healthcare industry, where he has served as the Chief Financial Officer of four publicly-traded healthcare companies," said Charlie Goodwin, President and

    11/28/23 8:30:00 AM ET
    $APYX
    $PDSB
    $SSKN
    Medical/Dental Instruments
    Health Care
    Biotechnology: Pharmaceutical Preparations

    STRATA Skin Sciences Appoints Dr. Uri Geiger to Chairman of its Board of Directors

    HORSHAM, Pa., June 30, 2023 (GLOBE NEWSWIRE) -- STRATA Skin Sciences, Inc. (NASDAQ:SSKN), a medical technology company dedicated to developing, commercializing and marketing innovative products for the treatment of dermatologic conditions, today announced the appointment of Dr. Uri Geiger as the Chairman of the Board of Directors. William Humphries will step down as Chairman and continue to serve on the Board, effective July 3, 2023, as he transitions into his role as Chief Executive Officer of Alcami Corporation. "I'm honored to assume the role of Chairman at this pivotal moment in STRATA's growth," said Dr. Uri Geiger, Chairman of STRATA's Board of Directors. "I look forward to levera

    6/30/23 8:00:00 AM ET
    $SSKN
    Medical/Dental Instruments
    Health Care

    STRATA Skin Sciences Appoints Patricia S. Walker, M.D., Ph.D. to its Board of Directors

    HORSHAM, Pa., Feb. 14, 2022 (GLOBE NEWSWIRE) -- STRATA Skin Sciences, Inc. (NASDAQ:SSKN), a medical technology company dedicated to developing, commercializing and marketing innovative products for the treatment of dermatologic conditions, announced that effective today, Patricia S. Walker M.D., PhD. has been appointed to its Board of Directors. Dr. Walker's vast experience includes more than 35 years as a practicing dermatologist and as a corporate leader in the medical dermatology, medical aesthetics and pharmaceutical industries, executing clinical research and strategic initiatives for a wide range of companies and educational institutions. "We are delighted to welcome Patty to STRAT

    2/14/22 4:05:00 PM ET
    $SSKN
    Medical/Dental Instruments
    Health Care

    $SSKN
    Financials

    Live finance-specific insights

    View All

    STRATA Skin Sciences Reports Second Quarter 2025 Financial Results and Provides a Corporate Update

    HORSHAM, Penn., Aug. 13, 2025 (GLOBE NEWSWIRE) -- STRATA Skin Sciences, Inc. ("STRATA" or the "Company") (NASDAQ:SSKN), a medical technology company dedicated to developing, commercializing, and marketing innovative products for the treatment of dermatologic conditions, announces its financial results for the quarter ended June 30, 2025, and provides a corporate update. Second Quarter Highlights Historic expansion of CPT codes for reimbursement for inflammatory and auto-immune skin diseases, effectively tripling the covered patient population in the USPotential acceleration of expanded reimbursement coverage through application for G-codes to gain access by 2026 cycleSubmission of econom

    8/13/25 4:05:00 PM ET
    $SSKN
    Medical/Dental Instruments
    Health Care

    STRATA Skin Sciences to Report Second Quarter 2025 Financial Results on August 13, 2025 and Provide Corporate Update

    HORSHAM, Pa., July 31, 2025 (GLOBE NEWSWIRE) -- STRATA Skin Sciences, Inc. ("STRATA" or the "Company") (NASDAQ:SSKN), a medical technology company dedicated to developing, commercializing, and marketing innovative products for the treatment of dermatologic conditions, announces that it will report second quarter 2025 financial results on Wednesday, August 13, 2025 after the market close. STRATA management will subsequently host a conference call at 4:30 p.m. ET on Wednesday, August 13, 2025 to review financial results and provide an update on corporate developments. Following management's formal remarks, there will be a question-and-answer session. To listen to the conference call, i

    7/31/25 8:15:00 AM ET
    $SSKN
    Medical/Dental Instruments
    Health Care

    STRATA Skin Sciences Reports First Quarter 2025 Financial Results and Provides a Corporate Update

    HORSHAM, Pa., May 14, 2025 (GLOBE NEWSWIRE) -- STRATA Skin Sciences, Inc. ("STRATA" or the "Company") (NASDAQ:SSKN), a medical technology company dedicated to developing, commercializing, and marketing innovative products for the treatment of dermatologic conditions, announces its financial results for the quarter ended March 31, 2025, and provides a corporate update. First Quarter 2025 Financial Highlights Revenue in the first quarter of 2025 was $6.8 million, up 1% Global net recurring XTRAC® revenue in the first quarter was $4.5 million vs. $4.6 million in the prior year period, with international growth of 27% offsetting a 4% decline in the domestic marketAverage net revenue per dome

    5/14/25 4:05:00 PM ET
    $SSKN
    Medical/Dental Instruments
    Health Care

    $SSKN
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Strata Skin Sciences Inc.

    SC 13G/A - STRATA Skin Sciences, Inc. (0001051514) (Subject)

    11/14/24 2:04:43 PM ET
    $SSKN
    Medical/Dental Instruments
    Health Care

    Amendment: SEC Form SC 13D/A filed by Strata Skin Sciences Inc.

    SC 13D/A - STRATA Skin Sciences, Inc. (0001051514) (Subject)

    7/18/24 7:42:09 PM ET
    $SSKN
    Medical/Dental Instruments
    Health Care

    SEC Form SC 13G/A filed by Strata Skin Sciences Inc. (Amendment)

    SC 13G/A - STRATA Skin Sciences, Inc. (0001051514) (Subject)

    2/14/24 4:51:41 PM ET
    $SSKN
    Medical/Dental Instruments
    Health Care